← Back to Search

Weekly Behavioral Coaching Session for Bipolar Disorder

N/A
Waitlist Available
Led By Tony George, M.D., FRCPC
Research Sponsored by Centre for Addiction and Mental Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All participants must be between the ages 18-60
Have a Full-Scale IQ of at least 80 as determined by the WTAR
Timeline
Screening 3 weeks
Treatment Varies
Follow Up bi-weekly (day 0, day 14, day 28) and at 8 weeks (follow-up day 56)
Awards & highlights

Study Summary

This study is evaluating whether a 28-day abstinence period can improve symptoms and cognition in patients with comorbid cannabis use disorder and bipolar disorder.

Eligible Conditions
  • Bipolar Disorder
  • Cannabis Use Disorder
  • Cognition

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weekly (day 0, day 7, day 14, day 21, day 28) and at 8 weeks (follow-up day 56)
This trial's timeline: 3 weeks for screening, Varies for treatment, and weekly (day 0, day 7, day 14, day 21, day 28) and at 8 weeks (follow-up day 56) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The effects of 28 day cannabis abstinence on change in depressive symptoms in cannabis-dependent patients with bipolar disorder as assessed by the Hamilton Rating Scale for Depression (HRSD).
The effects of 28 day cannabis abstinence on change in hypomania symptoms in cannabis-dependent patients with bipolar disorder as assessed by the Young Mania Rating Scale (YMRS).
Secondary outcome measures
The effects of 28 day cannabis abstinence on change in co-occurring anxiety in cannabis dependent patients with bipolar disorder as assessed by the Beck Anxiety Inventory (BAI).
The effects of 28 day cannabis abstinence on change in cognitive function in cannabis dependent patients with bipolar disorder as assessed by a cognitive battery administered at Baseline, Week 2, Endpoint and Follow-Up.

Trial Design

2Treatment groups
Experimental Treatment
Group I: No Contingent ReinforcementExperimental Treatment1 Intervention
The Non-Contingent Reinforcement (NCR) group (n=26) will not be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence.
Group II: Contingent ReinforcementExperimental Treatment1 Intervention
The Contingent Reinforcement (CR) group (n=26) will be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence verified by self-report and urinary THC-COOH level <20 ng/ml.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Weekly Behavioral Coaching Session
2017
N/A
~20

Find a Location

Who is running the clinical trial?

Centre for Addiction and Mental HealthLead Sponsor
354 Previous Clinical Trials
81,120 Total Patients Enrolled
13 Trials studying Bipolar Disorder
1,365 Patients Enrolled for Bipolar Disorder
Tony George, M.D., FRCPCPrincipal InvestigatorCentre for Addiction and Mental Health
1 Previous Clinical Trials
19 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Effects of Cannabis Abstinence on Symptomology and Cognition in Bipolar Disorder
Tony George 2018. "Effects of Cannabis Abstinence on Symptomology and Cognition in Bipolar Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03629106.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top